Rhythm Pharmaceuticals Releases EMANATE Trial Results for Setmelanotide
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Should l Buy RYTM?
Source: NASDAQ.COM
- Trial Overview: Rhythm Pharmaceuticals' global Phase 3 EMANATE trial results for Setmelanotide indicate that while primary endpoints were not met, significant BMI reductions of -9.7% and -8.0% were observed in POMC/PCSK1 and SRC1 heterozygous patients at 52 weeks, respectively, providing critical data for future treatment strategies.
- Patient Group Analysis: Among the four genetic subgroups, POMC/PCSK1 patients (n=78) showed a 4.3% BMI reduction, LEPR patients (n=23) a 3.6% reduction, SRC1 patients (n=73) a 4.0% reduction, and SH2B1 patients (n=121) a 1.7% reduction, highlighting the differential treatment responses based on genetic variants.
- Safety Assessment: No new safety concerns emerged during the trial, with common side effects including skin reactions, nausea, vomiting, and headache, indicating a favorable safety profile for Setmelanotide and supporting its broader application in the patient population.
- Future Development Directions: Rhythm plans to continue analyzing EMANATE data to guide development paths for SRC1 and POMC subgroups while advancing next-generation MC4R agonists Bivamelagon and RM-718, demonstrating the company's ongoing commitment to addressing rare genetic obesity.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RYTM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RYTM
Wall Street analysts forecast RYTM stock price to rise
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 82.590
Low
123.00
Averages
140.62
High
167.00
Current: 82.590
Low
123.00
Averages
140.62
High
167.00
About RYTM
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company’s lead asset, IMCIVREE, is an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the Food and Drug Administration (FDA) to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged four years and older with acquired hypothalamic obesity, adult and pediatric patients two years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. In addition to it the Company is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PANTHERx Selected as Exclusive U.S. Pharmacy Partner for IMCIVREE Distribution
- Exclusive Partnership: PANTHERx Rare Pharmacy has been selected by Rhythm Pharmaceuticals as the exclusive U.S. pharmacy distribution partner for IMCIVREE®, focusing on acquired hypothalamic obesity treatment, marking a significant expansion in the rare disease sector.
- Personalized Patient Support: PANTHERx will leverage its industry-leading RxARECARE® model to provide therapy-specific clinical expertise to patients, caregivers, and prescribers, making complex rare disease therapies more accessible through individualized case management and comprehensive financial and insurance navigation.
- Historic Milestone: The new indication for IMCIVREE offers crucial treatment options for patients with acquired hypothalamic obesity, with CEO Bansi Nagji highlighting its significance as a scientific milestone for affected individuals and families, demonstrating the company's commitment to high-touch clinical support.
- Industry Leadership: Since 2020, PANTHERx has served as the exclusive pharmacy partner for IMCIVREE in chronic weight management, further solidifying its position as the largest independent rare pharmacy in the U.S., showcasing its expertise and innovation in the rare disease field.
See More
PANTHERx Selected as Exclusive U.S. Pharmacy Partner for IMCIVREE Distribution
- Exclusive Partnership: PANTHERx Rare Pharmacy has been selected by Rhythm Pharmaceuticals as the exclusive U.S. pharmacy distribution partner for IMCIVREE, focusing on acquired hypothalamic obesity, which marks a significant expansion in the company's rare disease portfolio and is expected to enhance its market share and brand influence.
- Personalized Patient Support: PANTHERx will leverage its industry-leading RxARECARE® model to provide personalized clinical support and education to patients, caregivers, and prescribers, aiming to simplify the complex treatment processes associated with rare diseases and improve patient adherence and satisfaction.
- Historic Milestone: The new indication for IMCIVREE offers crucial treatment options for patients with acquired hypothalamic obesity, with CEO Bansi Nagji highlighting that this advancement brings hope to affected individuals and families, further solidifying the company's leadership in rare disease therapies.
- Industry Recognition: Since 2020, PANTHERx has been the exclusive pharmacy partner for IMCIVREE, focusing on obesity related to conditions like Bardet-Biedl Syndrome, and the company's successful track record and expertise will provide robust support for the promotion of this new indication.
See More
U.S. Stocks Decline Amid Rising Energy Costs and Inflation Fears
- Market Decline: The S&P 500 Index fell by 0.88% and the Nasdaq 100 Index dropped by 1.22%, both reaching 3.75-month lows, indicating market concerns over rising energy costs potentially impacting economic growth and inflation.
- Rising Bond Yields: The 10-year Treasury note yield rose to 4.38%, a 7.5-month high, reflecting market fears that surging energy prices from the Iran conflict will boost inflation and may force the Fed to tighten monetary policy.
- Escalating International Tensions: The Iran war has entered its 21st day with attacks on neighboring countries, leading Kuwait to shut down refinery units and Saudi Arabia and the UAE intercepting Iranian missiles, worsening market sentiment and increasing investor anxiety.
- Increased Market Volatility: With the quarterly triple witching event, approximately $5.7 trillion in options and derivatives are set to expire, potentially heightening market volatility and further intensifying investor unease.
See More
US Stocks Decline Amid Iran War Concerns
- Market Pressure Intensifies: The S&P 500 index fell by 0.37%, and the Nasdaq 100 dropped to a 3.75-month low as rising bond yields raised inflation concerns, indicating a pessimistic outlook for future economic conditions.
- Surging Energy Prices: The IEA reported that the Iran war is disrupting 7.5 million barrels per day of global oil supply, and the closure of the Strait of Hormuz has obstructed about one-fifth of the world's oil flow, potentially pushing crude prices above the 2008 record high of nearly $150 per barrel.
- Fed Policy Expectations: The market is pricing in only a 10% chance of a 25 basis point rate hike by the Fed at the April meeting, reflecting investor concerns over slowing economic growth, which could influence future monetary policy directions.
- Tech Stocks Decline: The
See More
Rhythm Pharmaceuticals Secures FDA Label Expansion for Setmelanotide
- FDA Approval Expansion: Rhythm Pharmaceuticals' lead asset, setmelanotide, has received FDA approval for use in patients with acquired hypothalamic obesity, a rare obesity disorder, allowing treatment for patients aged 4 and older, marking a significant advancement in the rare disease space.
- Clinical Trial Success: The Phase 3 TRANSCEND trial demonstrated that patients with acquired hypothalamic obesity achieved an average 15.8% reduction in body mass index (BMI), compared to a 2.6% increase in the placebo group, highlighting the product's efficacy and laying a solid foundation for market launch.
- Market Exclusivity: Imcivree is now the first and only FDA-approved therapy for acquired hypothalamic obesity, expected to be rapidly available to the targeted patient population, further solidifying Rhythm's leadership position in the rare obesity market.
- Financial Outlook: Rhythm anticipates non-GAAP operating expenses of $385 million to $415 million in 2026, as preparations for the launch of acquired hypothalamic obesity accelerate, presenting significant market opportunities and financial growth potential for the company.
See More
FDA Approves IMCIVREE for Hypothalamic Obesity Treatment
- FDA Approval: Rhythm Pharmaceuticals announced that IMCIVREE has received FDA approval, becoming the first and only therapy cleared for the treatment of acquired hypothalamic obesity, marking a significant breakthrough in this rare and severe condition.
- Clinical Trial Results: In the global Phase 3 TRANSCEND trial involving 142 patients, IMCIVREE achieved a placebo-adjusted BMI reduction of -18.4%, with treated patients showing a -15.8% mean BMI decrease compared to a +2.6% increase in the placebo group, demonstrating significant efficacy.
- Market Potential: With approximately 10,000 people in the U.S. living with acquired hypothalamic obesity, IMCIVREE is now available to U.S. patients, expected to meet the urgent needs of this specific population and drive revenue growth for the company.
- Revenue Growth: IMCIVREE generated $57.3 million in global net product revenue in Q4 2025, a 12% increase from $51.1 million in Q3, and a significant rise from $41.8 million in Q4 2024, indicating improved market acceptance.
See More
PANTHERx Selected as Exclusive U.S. Pharmacy Partner for IMCIVREE Distribution
- Exclusive Partnership: PANTHERx Rare Pharmacy has been selected by Rhythm Pharmaceuticals as the exclusive U.S. pharmacy distribution partner for IMCIVREE®, focusing on acquired hypothalamic obesity treatment, marking a significant expansion in the rare disease sector.
- Personalized Patient Support: PANTHERx will leverage its industry-leading RxARECARE® model to provide therapy-specific clinical expertise to patients, caregivers, and prescribers, making complex rare disease therapies more accessible through individualized case management and comprehensive financial and insurance navigation.
- Historic Milestone: The new indication for IMCIVREE offers crucial treatment options for patients with acquired hypothalamic obesity, with CEO Bansi Nagji highlighting its significance as a scientific milestone for affected individuals and families, demonstrating the company's commitment to high-touch clinical support.
- Industry Leadership: Since 2020, PANTHERx has served as the exclusive pharmacy partner for IMCIVREE in chronic weight management, further solidifying its position as the largest independent rare pharmacy in the U.S., showcasing its expertise and innovation in the rare disease field.
See More
PANTHERx Selected as Exclusive U.S. Pharmacy Partner for IMCIVREE Distribution
- Exclusive Partnership: PANTHERx Rare Pharmacy has been selected by Rhythm Pharmaceuticals as the exclusive U.S. pharmacy distribution partner for IMCIVREE, focusing on acquired hypothalamic obesity, which marks a significant expansion in the company's rare disease portfolio and is expected to enhance its market share and brand influence.
- Personalized Patient Support: PANTHERx will leverage its industry-leading RxARECARE® model to provide personalized clinical support and education to patients, caregivers, and prescribers, aiming to simplify the complex treatment processes associated with rare diseases and improve patient adherence and satisfaction.
- Historic Milestone: The new indication for IMCIVREE offers crucial treatment options for patients with acquired hypothalamic obesity, with CEO Bansi Nagji highlighting that this advancement brings hope to affected individuals and families, further solidifying the company's leadership in rare disease therapies.
- Industry Recognition: Since 2020, PANTHERx has been the exclusive pharmacy partner for IMCIVREE, focusing on obesity related to conditions like Bardet-Biedl Syndrome, and the company's successful track record and expertise will provide robust support for the promotion of this new indication.
See More
U.S. Stocks Decline Amid Rising Energy Costs and Inflation Fears
- Market Decline: The S&P 500 Index fell by 0.88% and the Nasdaq 100 Index dropped by 1.22%, both reaching 3.75-month lows, indicating market concerns over rising energy costs potentially impacting economic growth and inflation.
- Rising Bond Yields: The 10-year Treasury note yield rose to 4.38%, a 7.5-month high, reflecting market fears that surging energy prices from the Iran conflict will boost inflation and may force the Fed to tighten monetary policy.
- Escalating International Tensions: The Iran war has entered its 21st day with attacks on neighboring countries, leading Kuwait to shut down refinery units and Saudi Arabia and the UAE intercepting Iranian missiles, worsening market sentiment and increasing investor anxiety.
- Increased Market Volatility: With the quarterly triple witching event, approximately $5.7 trillion in options and derivatives are set to expire, potentially heightening market volatility and further intensifying investor unease.
See More
US Stocks Decline Amid Iran War Concerns
- Market Pressure Intensifies: The S&P 500 index fell by 0.37%, and the Nasdaq 100 dropped to a 3.75-month low as rising bond yields raised inflation concerns, indicating a pessimistic outlook for future economic conditions.
- Surging Energy Prices: The IEA reported that the Iran war is disrupting 7.5 million barrels per day of global oil supply, and the closure of the Strait of Hormuz has obstructed about one-fifth of the world's oil flow, potentially pushing crude prices above the 2008 record high of nearly $150 per barrel.
- Fed Policy Expectations: The market is pricing in only a 10% chance of a 25 basis point rate hike by the Fed at the April meeting, reflecting investor concerns over slowing economic growth, which could influence future monetary policy directions.
- Tech Stocks Decline: The
See More
Rhythm Pharmaceuticals Secures FDA Label Expansion for Setmelanotide
- FDA Approval Expansion: Rhythm Pharmaceuticals' lead asset, setmelanotide, has received FDA approval for use in patients with acquired hypothalamic obesity, a rare obesity disorder, allowing treatment for patients aged 4 and older, marking a significant advancement in the rare disease space.
- Clinical Trial Success: The Phase 3 TRANSCEND trial demonstrated that patients with acquired hypothalamic obesity achieved an average 15.8% reduction in body mass index (BMI), compared to a 2.6% increase in the placebo group, highlighting the product's efficacy and laying a solid foundation for market launch.
- Market Exclusivity: Imcivree is now the first and only FDA-approved therapy for acquired hypothalamic obesity, expected to be rapidly available to the targeted patient population, further solidifying Rhythm's leadership position in the rare obesity market.
- Financial Outlook: Rhythm anticipates non-GAAP operating expenses of $385 million to $415 million in 2026, as preparations for the launch of acquired hypothalamic obesity accelerate, presenting significant market opportunities and financial growth potential for the company.
See More
FDA Approves IMCIVREE for Hypothalamic Obesity Treatment
- FDA Approval: Rhythm Pharmaceuticals announced that IMCIVREE has received FDA approval, becoming the first and only therapy cleared for the treatment of acquired hypothalamic obesity, marking a significant breakthrough in this rare and severe condition.
- Clinical Trial Results: In the global Phase 3 TRANSCEND trial involving 142 patients, IMCIVREE achieved a placebo-adjusted BMI reduction of -18.4%, with treated patients showing a -15.8% mean BMI decrease compared to a +2.6% increase in the placebo group, demonstrating significant efficacy.
- Market Potential: With approximately 10,000 people in the U.S. living with acquired hypothalamic obesity, IMCIVREE is now available to U.S. patients, expected to meet the urgent needs of this specific population and drive revenue growth for the company.
- Revenue Growth: IMCIVREE generated $57.3 million in global net product revenue in Q4 2025, a 12% increase from $51.1 million in Q3, and a significant rise from $41.8 million in Q4 2024, indicating improved market acceptance.
See More
